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Background: Oesophageal adenocarcinoma or Barrett’s adenocarcinoma (EAC) is increasing in incidence and stratification of
prognosis might improve disease management. Multi-colour Fluorescence in situ hybridisation (FISH) investigating ERBB2, MYC,
CDKN2A and ZNF217 has recently shown promising results for the diagnosis of dysplasia and cancer using cytological samples.
Methods: To identify markers of prognosis we targeted four selected gene loci using multi-colour FISH applied to a tissue
microarray containing 130 EAC samples. Prognostic predictors (P1, P2, P3) based on genomic copy numbers of the four loci were
statistically assessed to stratify patients according to overall survival in combination with clinical data.
Results: The best stratification into favourable and unfavourable prognoses was shown by P1, percentage of cells with less than
two ZNF217 signals; P2, percentage of cells with fewer ERBB2- than ZNF217 signals; and P3, overall ratio of ERBB2-/ZNF217
signals. Median survival times for P1 were 32 vs 73 months, 28 vs 73 months for P2; and 27 vs 65 months for P3. Regarding each
tumour grade P2 subdivided patients into distinct prognostic groups independently within each grade, with different median
survival times of at least 35 months.
Conclusions: Cell signal number of the ERBB2 and ZNF217 loci showed independence from tumour stage and differentiation
grade. The prognostic value of multi-colour FISH-assays is applicable to EAC and is superior to single markers.
Within the last three decades the incidence of oesophageal
adenocarcinoma (EAC) has increased in Western countries and
exceeded the levels of other cancers (Blot, 1994; Heitmiller and
Sharma, 1994; Devesa et al, 1998; Vizcaino et al, 2002; Pohl and
Welch, 2005; Brown et al, 2008; Umar and Fleischer, 2008).
Otherwise, the 5-year survival of EAC has remained at less than
10% in the past two decades (Blot et al, 1991; Devesa et al, 1998).
EAC is believed to develop via a stepwise process from Barrett’s
metaplasia as a predisposing condition (Hamilton and Smith, 1987;
Hameeteman et al, 1989; Miros et al, 1991; Reid, 1991; Haggitt,
1994; Spechler, 1994, 2002). Within a reflux-metaplasia-dysplasia-
carcinoma sequence, chronic damage by gastro oesophageal reflux
leads to development of metaplastic Barrett’s epithelium (BE).
Further mutagenic events result in a low- to high-grade
intraepithelial neoplasia-dysplasia-sequence and finally in invasive
cancer (Spechler, 2002).
To detect EAC at an early, potentially curable stage, guidelines
for gastro oesophageal reflux disease (GERD) outline that patients
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with GERD might benefit from an early endoscopic evaluation for
Barrett’s oesophagus (BE), considering its conversion rate to EAC
of 0.5–1% per year (Peitz and Malfertheiner, 2007; Thomas et al,
2007). The gold standard in estimating the prognosis of EAC
remains to be clinical classifications like TNM and grading of EAC.
However, these classifications are not suitable for every situation,
for example, biopsy collection, and could be complemented by new
biomarkers (Cestari et al, 2007; Huang, 2010). In EAC the
detection of MDM2, VEGF and p53 have been suggested as
markers of poor prognosis, but showed contradictory results across
studies (Cavazzola et al, 2009; Prins et al, 2012; Renouf et al, 2013).
A recent multi-centric study (OCCAM group) identified DCK,
PAPSS2, SIRT2 and TRIM44 as prognostic biomarkers in EAC by
extensive gene expression profiling and immunohistochemistry
(Peters et al, 2010). New molecular methods like multiplex FISH
analysis could be utilised for predictive stratification of patients
with EAC to select individualised treatment.
Gain and loss of certain gene loci can contribute to the
progression from BE to EAC, but less is known about their
prognostic significance as biomarkers. As one example, CDKN2A
(previously known as p16; 9p21) is involved in the clonal
expansion of EAC progenitor cells (Barrett et al, 1999). Other
gene loci such as ERBB2 (also known as Her2) (17q12), MYC
(8q24) and ZNF217 (20q13.2) are also implicated in EAC
development. All these genomic loci have shown promising results
in detecting progression from BE to dysplasia and EAC in
oesophageal brush cytology specimens (Brankley et al, 2006; Rygiel
et al, 2007; Fritcher et al, 2008). Although it could be assumed that
functionally important markers for progression might have an
impact on prognosis in EAC, the Fluorescence In Situ Hybridisa-
tion (FISH) assay using multi-colour Locus-Specific Identifier (LSI)
probes has never been applied to advanced EAC.
In brief, the single markers in this multi-colour FISH assay are
characterised as follows:
ERBB2 is part of the human epidermal growth factor
receptor family. It stimulates cell proliferation using the
RAS-MAP-kinase pathway and blocks apoptosis using the mTOR
pathway. ERBB2 was first evaluated as a target for trastuzumab
therapy in invasive breast cancer, and later in gastric cancer and
EAC (Huober et al, 2006).
ZNF217, also known as Zinc finger protein 217, encoded by
ZNF217, blocks signals resulting from dysfunction and may
promote neoplastic transformation and progression of malignancy
(Huang et al, 2005).
ZNF217 has recently been implicated in ovarian cancer. There it
could be linked to activated PIK3CA signalling, which puts it in a
possible context to influence ERBB2 and MAPK signalling
(Hou et al, 2014; Yoda et al, 2014).
Cyclin-dependent kinase inhibitor 2A (CDKN2A, p16Ink4A),
also known as multiple tumour suppressor 1 (MTS-1), is a tumour
suppressor encoded by CDKN2A (Nobori et al, 1994). Alterations
such as loss of CDKN2A, usually by deletion, mutation or
promoter hypermethylation, cause increased risk of developing
malignant tumours such as adenocarcinoma, including EAC,
because of its function in cell cycle regulation (Igaki et al, 1994).
MYC is a regulator gene that encodes a transcription factor and
is located on chromosome 8. It is believed to regulate the
expression of 15% of all genes through binding to enhancer box
sequences. Mutations in MYC that cause its persistent expression
have been found in many cancers (Cotterman et al, 2008). This
leads to deregulated expression of genes involved in cell
proliferation and results in cancers like Burkitt’s lymphoma
(Hummel et al, 2006).
As a proof-of-principle, multiplex FISH analysis can be applied
to formalin-fixed paraffin-embedded (FFPE) tissue, for example,
for MYC and ZNF217 (Wiech et al, 2009).
In this study we have applied four locus-specific probes (ERBB2
(17q12), MYC (8q24), CDKN2A (9p21), ZNF217 (20q13.2)) to
FFPE EAC tissue specimens and assessed the prognostic value of
these markers. A large, clinically well-defined EAC patient group
with follow-up data was investigated on tissue microarrays (TMA).
MATERIALS AND METHODS
Patient samples, tumour classification and clinical data. One
hundred and thirty EAC patient tissue samples were collected at
the Institute of Pathology, Technical University of Munich (TUM)
from 1991 to 2004 as previously described (Langer et al, 2006;
Rauser et al, 2007). The presence of Barrett’s adenocarcinoma was
confirmed histologically according to the tumour site and
histological categories. None of the patients had received
neoadjuvant chemotherapy or radiation. The average patients’
age was 63.4 years, ranging from 33 to 83 years. The median
follow-up time was 43 months (see Table 1). All histological
samples were FFPE. The tumours were classified according to the
2002 WHO classification of tumours from 2002 and the 6th edition
of the TNM-classification for oesophageal tumours (Hamilton and
Aaltonen, 2000). Invasion into blood vessels, lymphatic vessels or
extension of tumour beyond submucosal gland tissue was
documented separately. All cases were re-evaluated by an
experienced pathologist (MS, TTR), including exact location of
the tumour area on haematoxylin/eosin-stained (HE) slides before
extracting tissue for the TMA. The clinical follow-up data were
assembled separately from patient records. Twenty tissue samples
of cardiac mucosa without metaplasia or dysplasia were used as
representative control tissues. National and local ethical guidelines
were followed.
TMA procedure. TMAs were constructed for each tumour as
described previously (Bubendorf et al, 2001; Klopocki et al, 2004;
Baumann et al, 2006). A representative tumour section was
selected from a HE section of the paraffin block with the centre and
representative region of tumour tissue identified (detailed in
Supplementary Technical Notes).
Four-colour FISH. Analysis of multi-colour FISH on TMA slides
is a suitable tool to identify specific genomic changes in tumours
(Schwarz et al, 2008). FISH was performed on FFPE slides as
previously described (Sassen et al, 2008). We used directly labelled
LSI probes for ERBB2 (17q12), MYC (8q24), CDKN2A (9p21) and
Table 1. Major characteristics of the EAC study group (N¼130)
Gender, n (%) Stage, n (%) Grade, n (%)
Median age (range) Male Female I IIA IIB III IV 1 2 3
63.5 years (33–83) 118 (90.8) 12 (9.2) 55 (42.3) 22 (16.9) 16 (12.3) 30 (23.1) 7 (5.4) 12 (9.2) 56 (43.0) 62 (47.7)
Abbreviation: EAC¼oesophageal adenocarcinoma.
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ZNF217 (20q13.2). The four-colour LSI FISH probe set was
provided by Abbott Molecular (Des Plaines, IL, USA) and applied
on TMA sections following the manufacturer’s protocols (detailed
information in Supplementary Technical Notes).
Signal evaluation by epifluorescence microscopy. Slides were
evaluated using a fluorescence microscope equipped with five
bandpass filters specific for DAPI and each probe signal (ERBB2
(green), MYC (blue), CDKN2A (red) and ZNF217 (gold,
Aristoplan from Leitz, Wetzlar, more details in Supplementary
Technical Notes): Images were obtained with a Plan-Apochromatic
lens (63 , numerical aperture 1.4) and an Axio-Cam MRm
camera (both from Zeiss, Jena, Germany). HE pictures were taken
with a Leica DM 4000 B and DFC 320 camera (Leica AG, Wetzlar,
Germany).
Enumeration and evaluation of FISH signals. To determine copy
numbers at ERBB2 (17q12), MYC (8q24), CDKN2A (9p21) and
ZNF217 (20q13.2) chromosomal loci, FISH signals for each of the
four probes were enumerated in 130 EAC specimens with
acceptable hybridisation quality. A conventional HE stain was
performed to identify tumour areas for FISH analysis, as well as
guarantee the representativeness of the TMA spots, and for
reference histology.
For each patient specimen, a representative tumour area was
selected for evaluation on one of the three replicate punch samples
on the TMA, and 50 consecutive tumour cells were counted in the
selected area. To assure the sampling method was representative, a
50-cell enumeration was conducted on all three punch samples of
10 individual, randomly selected EAC cases. The representation
and homogeneity of the selected tumour areas during TMA
generation was statistically confirmed for each of the four probes
(ERBB2 (17q12), MYC (8q24), CDKN2A (9p21) and ZNF217
(20q13.2)) in the three resulting data sets by student’s t-test and
interclass correlation (Cohen’s Kappa).
In the control group, 19 tissue specimens with acceptable
hybridisation quality were enumerated. Nuclei in the cardiac
glands were examined in the same way as the nuclei of tumour cells
in the carcinoma group. For quality control, two reviewers
experienced in FISH analysis evaluated at least 15% of all punches
and comparison of their results showed high agreement.
Statistical analysis. In total, 130 EAC patient specimens were
evaluated in this study. To select the final FISH parameter(s) that
have significant impact on patients’ overall survival, the enumer-
ated data for the 130 patients were split into two parts. A randomly
selected subset of 64 patients was used as the training dataset, and
the remaining subset of 66 patients was treated as the validation
dataset.
Multiple (430) FISH parameters derived from the copy
numbers of the four FISH–LSI probes were first evaluated as
possible prognostic indicators of overall survival within a training
subset; the statistically significant parameters were further
validated within the full 130-patient dataset. The FISH parameters
were created from all possible combinations of the four probes
used in the assay, and were derived either from percentages of cells
with an abnormal copy number of one or more probes, or from the
copy number ratios.
Correlations between FISH parameters and important clinical
variables (age, gender, tumour grade and stage), were evaluated
using the w2-test. Frequency tables were generated to show the
patient distribution within each level.
To select optimal cutoff values for each of the FISH parameters,
patients were categorised into FISH positive (þ ) and FISH
negative ( ) groups based on each of the possible cutoff values.
The log-rank test was used to compare overall survival between the
FISHþ and FISH groups. The hypothesis was that FISHþ
patients have worse overall survival than FISH patients. For each
FISH parameter, the optimal cutoff value separating patients into
favourable and unfavourable survival outcome groups was selected
as the value that yields the lowest log-rank P-value. The parameters
with log-rank P-valueso0.05 at the optimal cutoff value were
chosen for further analysis.
With the most promising FISH parameters selected and their
optimal cutoffs derived from the log-rank test, a multivariate Cox
proportional hazard model was used to select the final FISH
parameters after adjusting for key clinical factors (age, gender,
tumour grade and stage). This exercise was done using the training
dataset. Once the final model was selected, it was confirmed with
the validation dataset and applied to the full dataset. Furthermore,
Kaplan–Meier method was used to obtain the overall survival
curves, stratified by important FISH and clinical predictors,
together with the corresponding median overall survival time. All
analyses were performed using SAS (Version 8.2, SAS Institute
Inc., Cary, NC, USA).
RESULTS
Morphological homogeneity in different TMA punches from the
tumour centre correlates with FISH results. Initially a series of
10 tumour specimens were analysed. In HE staining, the punch
biopsies from tumour centres showed the same morphology,
cytology and tumour grading. To exclude molecular heterogeneity
in the tumour punches taken during TMA generation, three
separate sets of 50 consecutive cells were counted for each of our
individual probes. Student’s t-tests showed no significant differ-
ences between means and each counted subset; further on,
interclass correlation coefficients were calculated and showed
significant homogeneity between the chosen tumour punch
biopsies in the TMA (details in Supplementary Statistical Notes).
The effect of nuclear truncation is comparable in EAC tissue
and normal tissue. In this study, FISH analysis was performed on
histological specimens. In comparison to cytological specimens,
FISH on histologic tissues showed a loss of up to 30% owing to
nuclear truncation, which depends on slide thickness (Nielsen et al,
2012). The effect was equal in tumour and normal tissues. There
was no effect of the greater diameter of tumour cell nuclei vs those
of normal tissue (data not shown). Therefore, these FISH-stained
3 mm-thick TMA sections were deemed appropriate for FISH
analysis. In normal tissue the mean values of signals/cell for
CDKN2A, ERBB2, ZNF217 and MYC were determined to be 1.68,
1.78, 1.77 and 1.74, respectively.
Fluorescence in situ hybridisation parameters distinguish
between normal and malignant tissue. The multi-colour probe
set utilised in this study (ERBB2, MYC, CDKN2A and ZNF217,
Figure 1) was originally selected to aid in diagnosing dysplasia and
EAC in patients with Barrett’s metaplasia (Brankley et al, 2006).
We observed that EAC was associated with gains in the ZNF217
and ERBB2 signals. As expected, MYC also showed a slight gain in
signal, while CDKN2A showed a signal loss in EAC. MYC and
CDKN2A indicated malignancy, but revealed no further prognostic
potential when analysed in multivariate analysis. ERBB2 as a single
marker correlated with tumour grade.
Table 2 shows the performance of selected FISH parameters
with cutoffs (percentage of positive cells or ratio of two probe
signals) for normal tissue and EAC. As is evident from the table, we
confirmed that the probes used in this study were highly sensitive
and specific for EAC when compared to normal tissue, with the
highest sensitivity and specificity achieved with ERBB2 and
ZNF217, or composite parameters based on these loci.
Selected FISH parameters predict overall survival in EAC
patients. Multiple parameters derived from the copy numbers of
FISH in oesophageal adenocarcinoma BRITISH JOURNAL OF CANCER
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ERBB2, MYC, CDKN2A, and ZNF217 were screened by univariate
log-rank analysis of overall survival at multiple cutoff values within
a randomly selected training subset, as described in the Materials
and Methods section.
For each of the parameters, the optimal cutoffs were selected
that minimised log-rank P-values. Those parameters with optimal
cutoffs that were statistically significant at the 0.05 level were
selected as potential prognostic indicators of overall survival. The
selected parameters were further evaluated for significance in
univariate analysis with a validation data subset, as well as with the
complete 130-specimen dataset. With the selected cutoffs, para-
meters P1, P2 and P3 listed below were shown to have statistically
significant effects on survival in randomly selected training and
validation subsets of the data, as well as in the full dataset,
discriminating patients with longer median survival from those
with shorter survival times. Therefore, parameters P1, P2 and P3
were shown to dichotomise between favourable and unfavourable
outcomes with respect to overall survival:
 P1: percentage of cells with less than two signals for the ZNF217
locus, with favourable outcome below a cutoff of 16%.
 P2: percentage of cells with fewer ERBB2 than ZNF217 signals
(ERBB2/ZNF217o1), with favourable outcome observed at or
above a cutoff of 28%.
 P3: the overall ratio of ERBB2 to ZNF217 signals, with favourable
outcome observed below a cutoff of 1.5.
The results of the log-rank test for each of the selected
predictors in the combined full dataset of 130 patients are shown in
Table 3.
Analysis of covariates and proportional hazards model to
predict overall survival. As shown above, FISH parameters were
found to be potential predictors of survival. These parameters were
further evaluated in a covariate analysis with clinico-pathological
variables to understand the relative importance of molecular and
clinical parameters that might be associated with disease outcome.
Correlation between several clinico-pathological variables, as well
as correlation of these variables with FISH, was assessed in
univariate and multivariate (Cox proportional hazards) analyses,
testing the effect of these covariates on patient survival. The
clinico-pathological variables included anatomical stage (I, IIA, IIB,
III and IV), blood vessel invasion, lymphangiosis carcinomatosa,
depth of tissue infiltration (T-stage), lymph node status (N-stage)
and tumour grade. In a univariate analysis these were the best
predictors of survival. However, when entered in a multivariate
model, it was observed that the clinical parameters, including
lymph node status, were correlated with the anatomical stage.
Therefore, out of the clinical parameters tested, two were selected
for further analysis: tumour grade and anatomical stage.
Tumour grade and anatomical stage were also found to be
correlated with FISH parameters P1, P2 and P3. Therefore, a
stratified analysis was performed to assess the prognostic value of
FISH in the presence of these important clinico-pathological
covariates.
Multivariate model analysis of stratified data. The greatest
predictive power in stratifying the patient population in this study
was observed when FISH was combined with grade or stage in the
multivariate analysis (Figures 2–5 and Table 4). In the multivariate
model analysis carried out using SAS, the PHRED procedure,
statistical significance was achieved with both the training and
validation sets for all three FISH parameters (P1–P3, log-rank
Po0.0001). The model with the highest statistical scores of all
models possible for all given covariates is shown in Table 4. This
model is based on the entire patient group (complete dataset) and
reports survival times and hazard ratios for each FISH parameter.
Each of the predictors P1, P2 and P3 adds additional prognostic
information to histological grade. As is evident from Table 4,
each of the three FISH predictors, P1, P2 and P3 added prognostic
value to that of each histological grade in the common tripartite
grading system. Furthermore, defining the FISHþ group of
patients as those with poorer prognosis for each of the selected
FISH parameters, the same trend for a combination of all three
parameters combined (P positive defined as either P1, P2, or P3
positive) was shown in the survival analysis (Figure 5A). For each
grade, FISH (P) stratified patients into FISH positive and negative
groups based on the difference in the overall survival. For example,
in well differentiated tumours patients’ survival could be separated
A
B
C
D
Figure 1. (A) Oesophageal adenocarcinoma with HE staining (TMA):
magnification 400 , for verifying carcinoma cells against epithelium,
low- or high-grade dysplasia and normal soft tissue in between
tumour cells. (B) Oesophageal adenocarcinoma with HE staining
(TMA): magnification 500 , for counting and verifying carcinoma
tissue and epithelium, low- or high-grade dysplasia and normal soft
tissue. (C) Representative sample of EAC (TMA): FISH showing gain in
ERBB2 and ZNF217, loss of CDKN2A and unspecific signals for MYC.
Fluorescence in situ hybridisation–LSI probes for ERBB2 (green), MYC
(blue), CDKN2A (red) and ZNF217 (gold). Note the gain in strong
ERBB2 spots in comparison to the low number of ZNF217, indicating an
unfavourable EAC with regard to our predictors P1–P3. (D) Tissue from
normal cardiac mucosa with the FISH–LSI probes for ERBB2 (green),
MYC (blue), CDKN2A (red) and ZNF217 (gold) as the control group and
standard values.
Table 2. Performance of selected parameters based on FISH–LSI probes
and probe combinations in identifying EAC (130 EAC and 19 cardia
mucosa (normal control)), in order of descending sensitivity and
specificity
Parameter Cutoff Sensitivity Specificity
% Cells with ZNF217/CDKN2A41 435% 98% 95%
ZNF217/cell 42.0 96% 100%
ERBB2/cell 42.0 96% 95%
% Cells with gains in any two loci 420% 95% 100%
ERRB2/CDKN2A 41.2 94% 100%
% Cells with gains in any three loci 42.0% 93% 100%
Abbreviations: EAC¼oesophageal adenocarcinoma; FISH–LSI¼ fluorescence in situ
hybridisation–locus-specific identifier. Varied cutoff values were used for each FISH parameter
to calculate the sensitivity and specificity in discriminating EAC from normal controls.
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in longer than study duration in comparison to 59.67 months as
well as in poor differentiated tumours with a distinction of 47.0 vs
11.00 months, as is evident from Figure 5.
Fluorescence in situ hybridisation parameters and tumour
stages. In contrast, the contributions of P1, P2 and P3, as well
as the three parameters in combination, were more significant at
low stages (I and IIA), where FISH discriminated between
patients with favourable prognosis and those with survival similar
to that of higher-stage patients (IIB, III and IV) (Figures 2–4 and 5B).
Specifically, the effect was most significant for Stage IIA
patients (data not shown). As stage IIA and IIB differ by the
status of lymph node metastasis, it is possible that FISH allows
detection of a subset of patients with worse outcome, possibly
owing to occult metastasis, who may need to be re-evaluated for
treatment.
ZNF217/cell ratio and ERBB2/cell ratio influence. Fluorescence
in situ hybridisation parameters P1, P2 and P3, derived from the
copy number of ZNF217 loci per cell, have high-prognostic
value. Thus, we examined this FISH parameter in more detail.
ZNF217/cell did not show statistical significance in the initial
analysis; however, it was significant when combined with stage or
grade (Figure 6). Interestingly, we found evidence that a relatively
low level of ZNF217/cell (o2.8) was associated with a poorer
prognosis, similar to the trend observed with P1 and P2 (Figure 6),
while higher ratios were associated with a more favourable
outcome. This trend was consistent with the effect of ZNF217
copy number on P1, P2 and P3.
In contrast, the ERBB2/cell number was directly correlated with
poorer prognosis. We found a significant correlation between
ERBB2 gain and poorer survival. Kaplan–Meier survival analysis
indicated a median survival time greater than the study duration
for patients with low ERBB2 copy number (o43% cells with
ERBB2 42 signals/cell) and 43 months for patients with higher
copy number (Supplementary Figure 1A). This trend is consistent
with the effect of ERBB2 copy number on P2 and P3. So besides the
three predictors P1–P3, the percentage of cells with ERBB2 42
signals/cell may serve as a predictor.
Combining ERBB2 and ZNF217 into a ratio to yield a single
predictor was fulfilled with our predictor P3, which could be used
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Figure 2. Predictor 1 (P1): P1 discriminates patient survival the best in low-stage groups. Kaplan–Meier survival analysis of P1: percentage of cells
with less than two signals for ZNF217. Best dichotomization of data for favourable outcome below a cutoff of 16%. Results grouped by clinical
stage. Median survival in months for each category is shown in parentheses (log-rank test, Po0.0001).
Table 3. Univariate survival analysis of the selected FISH predictors P1, P2 and P3 (different combinations of ERBB2 and ZNF217, analysed by SAS,
favourable and unfavourable groups in months, hazard ratio (HR) and P-value in log-rank test)
Median Survival Median values Log-rank test
Predictor and definition Favourable Unfavourable Favourable Unfavourable HR P-value
P1: % of cells witho2 ZNF217 signals, cutoff 16% 72.7 33 6.00 20.00 1.764 0.0267
P2: % of cells with ERBB2oZNF217 signals, cutoff 28% 72.7 31.3 26.53 52.00 1.996 0.0066
P3: Overall ratio of ERBB2/ZNF217 signals, cutoff 1.5 65.2 27.3 0.94 2.15 2.112 0.0086
Abbreviation: FISH¼ fluorescence in situ hybridisation.
FISH in oesophageal adenocarcinoma BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.238 2989
0.9
0.8
0.7
0.6
0.5
Su
rv
ivi
ng
 (p
rop
ort
ion
 of
 ov
era
ll s
urv
iva
l)
0.4
0.3
0.2
0.1
0.0
Stage Log-rank P-value(FISH within stage)
0.8761
0.0032
Unfavourable
Unfavourable
FISH status Number ofpatients
55
19
31
21
42
9
6
4
Number
surviving
Median survival
(months) Plot line
> Study duration
49.00
19.00
22.00
Favourable
Favourable
IA and IIA
IIB, III and
IV
0 20 40 60 80 100 120 140 160
Lifetime (months)
1.0
Figure 3. Predictor 2 (P2): P2 is able to separate patients with low-stage tumours into groups with good and poor prognosis. Kaplan–Meier
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clinical stage. The late crossing of the curves in high-stage groups is owing to the small number of patients with these tumour stages. Median
survival in months for each category is shown in parentheses (log-rank test, Po0.0001).
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as a separate prognostic marker for the whole study collective
(Supplementary Figure 1B).
DISCUSSION
The clinical management of EAC is still limited in stratifying
patients into prognostic groups (Esofago, 1991) and a search for
comprehensive markers to improve disease management is
warranted (Ong et al, 2010; Moyes and Going, 2011).
Biomarkers in EAC are being investigated with a plethora of
molecular techniques. In addition to classical histology, immuno-
histochemistry, methylation patterns or genetic aberrations like
LOH of a certain chromosomal region (Albrecht et al, 2004; Ong
et al, 2010), as well as single nucleotide polymorphism microarray
(SNP-chip), are being utilised as research tools, but still lack
clinical significance (Akagi et al, 2009; Wiech et al, 2009).
Regarding prognosis, MDM2, VEGF and p53 evolved as
additional single markers in EAC but don’t seem to be robust
across studies (Cavazzola et al, 2009; Prins et al, 2012; Renouf et al,
2013). Hence, extending the analysis to multiple targets and
evaluating its feasibility for routine protocols is required.
Fluorescence in situ hybridisation meets these criteria.
Multi-colour FISH used on cytological oesophageal brushing
specimens has shown potential to serve as a diagnostic tool to
determine the progression from BE to high-grade dysplasia and
EAC with high sensitivity and specificity (Fritcher et al, 2008).
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Figure 5. A combination of predictors is able to identify individuals with a poorer prognosis in low- and high-tumour stages (A), and by grade in
the standard tripartite grading system (B). Prognosis grouped by histological grade or stage and FISH results, favourable if one of the three FISH
predictors P1–P3¼P is favourable in Kaplan–Meier survival analysis. Median survival in months for P for each category is shown in tables under the
plots. Regarding stage (A), FISH results separate low stages IA and IIA significantly (log-rank test Po0.0001) but not higher stages (log-rank test,
P¼0.8060). Regarding grade (B), FISH results tend to separate G1 EAC (log-rank test, P¼ 0.0586), G2 EAC not significantly (log-rank test,
P¼0.5596), but especially G3 EAC (log-rank test P¼0.0007).
Table 4. Multivariate survival analysis of the selected FISH predictors stratified by grade
Grade 1 Grade 2 Grade 3
Median survival Median survival Median survival
Predictor Favourable Unfavourable Favourable Unfavourable Favourable Unfavourable HR
P1 4study duration 59.7 86.5 42.0 43.0 11.0 2.193
P2 4study duration 54.3 86.5 40.0 46.8 12.0 2.529
P3 4study duration No patient 86.5 40.0 38.4 11.0 2.513
FISH 4study duration 59.7 86.5 47.0 47.0 11.0 2.463
Abbreviation: FISH¼ fluorescence in situ hybridisation. Also shown is the overall FISH status, defined as: if any one, or any combination of the three predictors is positive, the overall FISH status
is positive; otherwise, the status is negative (hazard ratio (HR), analysed by SAS, PHRED Procedure, median survival in months).
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This probe set consisting of ERBB2, CDKN2A, ZNF217 and MYC
was transferred to manifested EAC to address a possible prognostic
impact. To our knowledge this is the first study in EAC combining
FISH biomarkers with outstanding clinical follow-up data on 130
individuals over 160 months.
We defined three essential predictors of overall survival: P1, P2
and P3, and compared them to the clinico-pathological
parameters in univariate and multivariate analysis (Cox propor-
tional hazards) to analyse the effect of these covariates on patient
survival. We determined that each of the FISH parameters added
additional predictive information independent of histological
grade. Thus, FISH may be able to detect individuals with high-
risk EAC, adding information to the classical histopathological
staging (Figures 2–4).
In patient follow-up of over 160 months, all three FISH
parameters P1, P2 and P3 predicted significant survival differences
of about 40 months. This allowed the identification of patients with
at least 25% prolonged lifetime. We further developed a subgroup
analysis in low- and high-grade stages (I and IIA vs IIB, III and IV).
Fluorescence in situ hybridisation predictors were able to better
distinguish favourable and unfavourable outcomes in low tumour
stages. Hence, the useful multi-colour FISH approach for the
analysis of progression from BE to EAC in brush cytology sends
further light on EAC’s prognosis (Brankley et al, 2012; Yao et al,
2008). In detail, the biomarkers ZNF217 and ERBB2 added more
prognostic significance than CDKN2A or MYC. The latter still
provided diagnostic power for detection of EAC. As seen from
Table 2, all four gene loci are increased in EAC at high sensitivity
and specificity, but our data support a particular role of ZNF217
and ERBB2 in EAC.
Taking a closer look at the effect of the ZNF217 locus on
survival, ZNF217 showed a relatively low-level gain that was
associated with a poorer prognosis, while higher copy number
was linked to better outcome. Low-level gain in ZNF217, in
contrast to high-copy number, appears to be unfavourable for
survival in this analysis. This interesting finding may be related
to the notion that initial genomic instability is followed by the
selection of more stable tumour cells with low-level to
moderately amplified ZNF217 in aggressive cancer cells, similar
to ovarian clear cell carcinoma (Rahman et al, 2012). Our finding
that EAC patients possessing higher copy number ZNF217 have
better outcomes contrasts to literature reports, where Huang et al
(2005) showed that a higher copy number of ZNF217 was
associated with a poorer prognosis in breast cancer. Littlepage
et al (2012) showed that ZNF217 as a candidate oncogene could
be a target of treatment in breast cancer and is associated with
poor prognosis. Those findings regarding ZNF217 seem not to be
a universal phenomenon and actually are still under debate. Our
data on ZNF217 are so far the first correlated to prognosis in
EAC. It seems that ZNF217 has a different role in EAC prognosis
as compared with breast cancer. In our study the clinical
associations of the three predictors (P1–P3) have in common the
finding that higher levels of ZNF217 are associated with better
outcome.
ERBB2 represents the second essential part of our predictors
(P1–P3). Knowledge about Her2/ERBB2 has grown substantially
within the last years since the introduction of trastuzumab as a
targeted therapy for gastric cancer and EAC as well (Ross and
McKenna, 2001; Bookman, 2003; Gravalos and Jimeno, 2008;
Aitken et al, 2010; Bang et al, 2010; Ru¨schoff et al, 2010). It is
known that up to 25% of EACs overexpress Her2/ERBB2 in
immunohistochemistry or FISH analysis. These patients might
therefore be eligible for targeted therapy and benefit from a
therapy-associated better outcome. Assessment of ERBB2 by means
of a theranostic marker evoked the problem of tumour hetero-
geneity in EAC. It is strongly recommended to use whole tumour
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Figure 6. ZNF217/cell serves as a predictor and subdivides individuals into stage groups and within each grade according to prognosis.
Kaplan–Meier survival analysis of the FISH parameter ZNF217/cell; definition and cutoff: ZNF217/cell with a cutoff of 2.8 and a favourable outcome
above the cutoff, grouped by clinical stage (A), and histological grade (B). ZNF217/cell and stages I and IIA, III and IV (log-rank test, Po0.0001);
ZNF217/ cell and grades 1–3 (log-rank test, P¼0.0009). Median survival in months for each category is shown in tables under the plots.
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sections for diagnostic purposes. Additionally, immunohistochem-
istry was judged superior to FISH analysis as it maintains an
overview of a possibly heterogeneous cancer sample (Ru¨schoff et al,
2010, 2012). In a study setting, TMA techniques are generally very
useful for the simultaneous analysis of large sample numbers, as in
our case. TMA generation itself is targeted on homogeneity in
collected core biopsies. Possibly this is the reason behind our
more homogenous ERBB2 results. The perspectives of whole slide
imaging and analysis by automated digital pathology will
be applicable for Multi-colour FISH analysis in the near future
(Dobson et al, 2010; Braun et al, 2013; Furrer et al, 2013). This will
enable a concrete mapping of tumour heterogeneity with FISH
comparable to immunohistochemistry. Beyond theranostic aspects,
the role of ERBB2 as a prognostic marker is still under debate
(Bang et al, 2010). We found a significant correlation between low
levels of ERBB2 and better outcome and an association with
tumour grade and stage. Specifically, low copy number of ERBB2,
which in this context is statistically defined as less than 43% of cells
with ERBB2 42/cell, was significantly associated with improved
survival (Supplementary Figure 1A). This is in line with a recent
meta-analysis showing 7 months of gain in survival in patients
without Her2/ERBB2 expression. However, Gowryshankar et al
(2014) also referred to the heterogeneous results of the prognostic
impact of ERBB2 in EAC among different studies (Tanner et al,
2005; Gravalos and Jimeno, 2008; Yoon et al, 2012a, b).
To obtain more objective detection methods and classifications
of Her2/ERBB2, positivity should be standardized for study
purposes, for example, with the envisioned partially automated
sample scoring system (Dobson et al, 2010).
This is particularly mandatory as multiplex approaches
complicate the number of possible combinations—we calculated
n430 mathematical terms—and might imply confusing thresh-
olds. This accounts for our markers P1 and P2, which achieved the
best discriminative P-values, but might be regarded as counter-
intuitive with respect to their definitions and cutoffs.
Fluorescence in situ hybridisation parameters defined as ratios
are more convenient. Thus, P3 is described as the overall ratio of
the ERBB2 to ZNF217 signals. Its cutoff is set at 1.5 and maintains
high significance. That makes P3 the most valuable for current
routine diagnostics. Additionally, ratio-based FISH predictors are
advantaged as they are less dependent on the thickness of slides or
nuclear truncation (see additional Supplementary Technical
Notes). However, the combination of all three predictors (P1–P3)
added the utmost prognostic value in our study.
In conclusion, we see great advantage in analysing several
biomarkers in a single assay. This can be demonstrated by multi-
colour FISH in comparison to single marker approaches, for
example, investigation of p53, MDM2 and VEGF in EAC (Reid
et al, 2001; Cavazzola et al, 2009; Prins et al, 2012; Renouf et al,
2013). An extensive whole genome analysis from the OCCAM
group detected DCK, PAPSS2, SIRT2 and TRIM44 as potential
prognostic biomarkers on the transcriptional and immunohisto-
chemical level (Peters et al, 2010). Taking into account that tumour
genetics and gene expressions interfere in a complex manner, FISH
is an ancillary approach investigating prognosis in EAC. Our
multi-colour-FISH assay is easy to use, ready for clinical
application on FFPE-material, and combines the sensitivity,
specificity and diagnostic value of CDKN2A, ZNF217, ERBB2
and MYC and the prognostic value of ZNF217 and ERBB2 into
predictors like P1, P2 and P3. In particular the predictor P3 seems
to be appropriate for diagnostic feasibility (Supplementary
Figure 1B). In addition, it is important to note that our predictors
P1–P3 were not planned a priori and, therefore, the definitions and
their results might require validation in an independent study. All
predictors might provide an additive opportunity for early
intervention and improved outcome in patients with EAC (Reid
et al, 2001; Quaroni et al, 2009).
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